Form 4: IO Biotech Executive Acquires Stock Options

Devin Whittemore Smith, General Counsel of IO Biotech, acquired stock options for 185,000 shares of common stock on March 15, 2024.

Summary

• On March 15, 2024, Devin Whittemore Smith, the General Counsel of IO Biotech, acquired stock options for 185,000 shares of the company's common stock at an exercise price of $1.65.
• The options vest over time, with one-fourth vesting on March 15, 2025, and the remainder vesting monthly thereafter, contingent upon continued service.
• The options have an expiration date of March 15, 2034.
• The vesting of these options is subject to acceleration under certain termination scenarios.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of options could be seen as a positive sign of the executive's confidence, but it's not a strong indicator.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of the regulatory landscape, providing transparency into the transactions of company insiders. This filing indicates the acquisition of stock options, a common form of executive compensation in the biotech industry.

Stakeholder Impact

• The granting of stock options could potentially align the interests of the General Counsel with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates